SI1: Survey on seasonal influenza vaccine among Algerian healthcare workers

Age :……

Sex ◯ Female

◯ Male

Marital status ◯ Married

◯ Single

Profession: ……

Experience ◯ Less than 5 years

◯ 10-6years

◯ 20-11years

◯ More than 20 years

Sector ◯ Private

◯ Public

Place of work ◯ Commune

◯ Daïra

◯ Department

Are you suffering from allergy? ◯ Yes ◯ No

Do you smoke? ◯ Yes ◯ No

Have you been affected by COVID-19 ? ◯ Yes ◯ No

Have you got COVID-19 vaccine? ◯ Yes ◯ No

Are you suffering from chronic diseases ◯ Yes ◯ No

If yes, which disease?.....

Knowledge about seasonal influenza:

Please answer to these questions

Item	Yes	No	I don't know
Influenza causes mild symptoms only; therefore, it cannot be considered a serious disease			
Influenza can cause severe illness or death			
Influenza can be transmitted through droplets and aerosols from coughing or sneezing			
Influenza can be transmitted via blood and body fluids			
People may spread influenza even without symptoms			
Influenza may be spread by touching one's mouth or nose with contaminated hands			
People may contract influenza even if they have previously contracted influenza			
Mask wearing can limit the spread of Influenza.			
HCWs can transmit seasonal influenza to their patients			
HCWs are at high risk of contracting seasonal flu			

Knowledge about seasonal influenza vaccine:

	Yes	No	I don't know
The influenza vaccine is effective at preventing influenza			
The influenza vaccine is composed of inactivated viruses			
The influenza vaccine reduce the risk of hospitalization and death			
The vaccine may decrease the days of illness from influenza			
The influenza vaccine causes flu-like symptoms			
Influenza vaccination reduces absenteeism from work			
Vaccinating healthcare workers against influenza helps to protect patients from severe illness or death			

Attitude toward Seasonal influenza vaccine:

Have you got the vaccine before the COVID-19 pandemic?	Yes
	No
Have you got the vaccine during the COVID-19 pandemic?	Yes
	No
Have you got the vaccine during this year?	Yes
	No
Has your attitude toward the vaccine changed due to	Yes (for vaccination)

the COVID-19?	Yes (against vaccination)
	No
Are you for or against Seasonal flu vaccination?	For vaccination
	Against vaccination
	Neutral

Have you got the vaccine before the COVID-19 pandemic? ◯ Yes ◯ No

Have you got the vaccine during the COVID-19 pandemic? ◯ Yes ◯ No

Have you got the vaccine during this year? ◯ Yes ◯ No

Has your attitude toward the vaccine changed due to the COVID-19?

- ◯ Yes (for vaccination)
- ◯ Yes (against vaccination)
- ◯ No

Are you for or against Seasonal flu vaccination?

- ◯ For vaccination
- ◯ Against vaccination
- ◯ Neutral

If you are for vaccination, what are your motivators?.....

- ◯ To protect my family
- ◯ To protect my patients
- ◯ To protect my self
- ◯ Because Seasonal flu could be a serious disease
- ◯ Because the vaccine is recommended by Health authorities/WHO
- ◯ Because the vaccine is effective
- ◯ Because the vaccine is safe
- ◯ Because the vaccine is free of costs

If you are against vaccination, why? ……

- ◯ I am concerned about possible adverse events from the vaccine
- ◯ The vaccine is not effective in preventing the flu
- ◯ Flu is not a serious illness
- ◯ Vaccines are primarily an economic business of pharmaceutical companies
- ◯ By following healthy lifestyles, I can avoid diseases without needing to get vaccinated
- ◯ I have little chance of contracting the disease
- ◯ I have a healthy body
- ◯ The vaccine is more dangerous than the virus itself
- ◯ If I contract the disease, the consequences will not worry me

What are your recommendation regarding seasonal influenza vaccine?

- ◯ We need more information on the composition of the vaccine and its side effects
- ◯ Vaccination of people at risk against influenza should be compulsory in Algeria
- ◯ Vaccination of health personnel against influenza should be compulsory in Algeria
- ◯ Programming awareness campaigns about the influenza vaccine

Do you recommend the vaccine for your family members/friends? ……..

SI2: STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract Cross-Sectional study as stated in title and abstract on the page 1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found A summary of study is provided in the abstract on page 1
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Mentioned in the introduction on page 2
Objectives	3	State specific objectives, including any prespecified hypotheses Mentioned in the introduction on page 2 (Lines 86-87)
Methods		
Study design	4	Present key elements of study design early in the paper Present in Methods section-Study design sub-heading on page 2-3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Present in Methods section-Study design sub-heading on page 3
Participants	6	(*a*) *Cohort study*—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up *Case-control study*—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls *Cross-sectional study*—Give the eligibility criteria, and the sources and methods of selection of participants Present in Methods section- Inclusion/Exclusion criteria sub-heading on page2-3 (Lines 99-100)
		(*b*) *Cohort study*—For matched studies, give matching criteria and number of exposed and unexposed *Case-control study*—For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable N/A
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Present in Methods section-Study tool sub-heading on pages 3 (Lines 120-137)

Bias	9	Describe any efforts to address potential sources of bias Present in Methods section- Inclusion/Exclusion criteria sub-heading on page 3
Study size	10	Explain how the study size was arrived at Present in Methods section-Study design sub-heading on page 3 (Lines 114-118)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Present in Methods section-Statistical analysis sub-heading on page 3 (Lines 132-137)
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding Present in Methods section-Statistical analysis sub-heading on page 4 (Lines 139-146).
		(*b*) Describe any methods used to examine subgroups and interactions Present in Methods section-Statistical analysis sub-heading on page 4
		(*c*) Explain how missing data were addressed Present in Methods section- Inclusion/Exclusion criteria sub-heading on page 4
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed *Case-control study*—If applicable, explain how matching of cases and controls was addressed *Cross-sectional study*—If applicable, describe analytical methods taking account of sampling strategy
		(*e*) Describe any sensitivity analyses No any sensitivity in analyses

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Not necessary in our study
		(b) Give reasons for non-participation at each stage Not necessary in our study
		(c) Consider use of a flow diagram Not necessary in our study
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Mentioned in Results section on page 4 (Line 149-159)
		(b) Indicate number of participants with missing data for each variable of interest Participants with missing data were excluded as mentioned in the methods section-Inclusion/Exclusion criteria sub-heading on page 4 (Lines 149-150)
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time
		Case-control study—Report numbers in each exposure category, or summary measures of exposure

		Cross-sectional study—Report numbers of outcome events or summary measures All outcomes are mentioned in the results section on pages 4-9
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included N/A
		(*b*) Report category boundaries when continuous variables were categorized N/A
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses N/A
Discussion		
Key results	18	Summarise key results with reference to study objectives Mentioned in the discussion section on pages 9 (Lines 233-237)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Mentioned on page 11 (Lines 342-348)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence As mentioned in the discussion section on pages 9-11
Generalisability	21	Discuss the generalisability (external validity) of the study results Mentioned on page 11
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Mentioned on page 12

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.